Financial Performance Highlights
Gujarat Kidney reported strong financial results for FY2025-26 with consolidated revenue of ₹820.13 crore (103.80% growth) and net profit of ₹154.97 crore (65% growth). Standalone performance showed revenue of ₹4010.02 lakhs (14% growth) and profit after tax of ₹990.14 lakhs (8.70% growth). The company completed its IPO in December 2025, raising ₹250.80 crore through issuance of 2,20,00,000 equity shares at ₹114 per share.
AGM Details and Corporate Governance
The 7th Annual General Meeting is scheduled for September 28, 2026, where shareholders will vote on multiple resolutions including:
- Appointment of two new independent directors (Mr. Paresh Dhoti and Mrs. Disha Bharpoda)
- Significant increases in remuneration for executive directors (Managing Director from ₹18 lakh to ₹36 lakh, Whole-time Director from ₹18 lakh to ₹24 lakh)
- Approval for borrowing limits up to ₹500 crore and related party transactions framework
- Appointment of secretarial auditors for 5 years
The board comprises 8 directors including 2 executive directors and 5 independent directors, with 18 board meetings conducted during the year.
Acquisitions and Business Expansion
The company executed several acquisitions during the year:
- Parekhs Hospital: ₹790.13 crore consideration
- Harmony Medicare: ₹155.56 crore consideration
- Patel Multispeciality Hospital: ₹50.00 crore consideration
- Total goodwill generated from acquisitions reached ₹907.32 crore
IPO proceeds utilization included ₹77 crore for Parekhs Hospital acquisition, ₹12.40 crore for Ashwini Medical Centre, and ₹10.78 crore for additional stake in Harmony Medicare. The company varied its IPO objects to include healthcare expansion in Bharuch and dialysis services collaboration.
Financial Position and Ratios
The company's financial position strengthened with property, plant and equipment at ₹454.33 crore, goodwill at ₹907.32 crore, and cash balances of ₹132.82 crore. Key ratios showed mixed performance:
- Current ratio improved significantly to 3.76 (from 1.01)
- Return on equity declined to 6.14% (from 36.61%) due to expansion
- Debt-equity ratio decreased to 0.06 (from 0.15)
Subsidiaries and Regulatory Matters
The company has multiple subsidiaries including Harmony Medicare (100%), Raj Palmland Hospital (51%), and Parekhs Hospital (100%). Regulatory actions included penalties from RoC (₹12,80,000) and stock exchanges (₹3,30,400 each from BSE/NSE) for compliance matters. The company reported no benami properties, crypto currency investments, or wilful defaulter status.
Corporate Structure and Shareholding
Paid-up equity share capital stands at ₹157.69 crore with promoter shareholding at approximately 72.46%. The company operates in the medical and healthcare services segment across India with significant related party transactions including ₹108.91 crore in director remuneration and ₹268.77 crore in advances to related parties.